BluMaiden BioScience

Executive Summary

BluMaiden BioScience is a Singapore-based biotechnology company that leverages artificial intelligence-guided computational genetics and chemistry to discover novel therapeutics derived from human natural products. Founded in 2020, the company’s platform decodes human-derived small molecules to generate biocompatible drug candidates, with a primary focus on oncology and immunology. By tapping into the human body’s own natural defenses, BluMaiden aims to create safer, more effective treatments with reduced side effects, addressing significant unmet medical needs. The company employs 50–200 staff and operates at the preclinical stage, positioning itself as an innovative player in the emerging field of AI-driven drug discovery from endogenous compounds.

Upcoming Catalysts (preview)

• Q4 2026Completion of Lead Optimization for Lead Oncology Candidate60% success
• Q2 2027Initiation of IND-Enabling Studies for Pipeline Program50% success
• TBDStrategic Partnership or Licensing Deal for AI Platform40% success